Rituximab: Applications in dermatology
- 1 October 2006
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (10), 1143-1155
- https://doi.org/10.1111/j.1365-4632.2006.03007.x
Abstract
Rituximab is a chimeric anti-CD20 monoclonal antibody which has been used extensively for B-lymphocytic malignancies. In addition, applications for autoimmune diseases have emerged in recent years. Case reports support the use of rituximab in certain dermatologic conditions, including paraneoplastic pemphigus, pemphigus vulgaris, graft versus host disease, and cutaneous B-cell malignancies. Clinical trials are lacking and would be an appropriate next step.Keywords
This publication has 88 references indexed in Scilit:
- Progression of classic Kaposi's sarcoma with rituximabJournal of the American Academy of Dermatology, 2005
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Treatment of primary cutaneous B-cell lymphoma with rituximabJournal of the American Academy of Dermatology, 2005
- Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphomaBritish Journal of Dermatology, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004
- Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximabJournal of the American Academy of Dermatology, 2003
- Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximabZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Systemic Therapy of Primary Cutaneous B-cell Lymphoma, Marginal Zone Type, with Rituximab, a Chimeric Anti-CD20 Monoclonal AntibodyPublished by Medical Journals Sweden AB ,2001
- Paraneoplastic Pemphigus: A Case of Prolonged SurvivalMayo Clinic Proceedings, 1994